title: Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
abstract: BACKGROUND
  Given increasing rates of resistance to existing therapy, new options for treatment and prophylaxis of malaria are needed.
  
  
  METHODS
  Two randomised, comparative, non-inferiority studies were conducted in Africa, one double-blinded and one open-label. Adults with fever, a positive peripheral blood smear, and a positive rapid diagnostic test for Plasmodium falciparum were randomised in both studies to either azithromycin (AZ) 1,000 mg plus chloroquine (CQ) 600-mg base (AZCQ 1,000 mg) once daily for three days or mefloquine hydrochloride (MQ) 1,250 mg (split dose). In the first study, an additional regimen of AZ 500 mg plus CQ 600-mg base (AZCQ 500 mg) once daily for three days was included. All study participants were hospitalised until three consecutive daily blood smears were negative for asexual P. falciparum parasitaemia. Study participants were evaluated weekly for 42 days, with Day 28 polymerase chain reaction (PCR)-corrected parasitological clearance rate as primary endpoint.
  
  
  RESULTS
  A total of 467 subjects were randomised in the two studies. At 28 days' follow-up, PCR-corrected parasitological clearance rates in the per protocol population in the first study were 101/103 (98%) with AZCQ 1,000 mg compared with 102/103 (99%) with MQ (95% confidence interval [CI]: -5.2, 3.3). The AZCQ 500-mg regimen was stopped during an interim study review (six [86%] clearance of seven evaluable; two lost to follow-up). In the second study, clearance rates were similar: AZCQ 1,000 mg 107/107 (100%) vs MQ 111/112 (99%; 95% CI: -1.8, 3.6). Among the participating countries, in vitro CQ resistance based on pfcrt mutation frequency in the baseline isolates across both studies ranged from 20.8% (Zambia) to 96.1% (Uganda). Serious adverse events (AEs; all causality) were observed more frequently with MQ compared with AZCQ (four vs one, respectively), though discontinuations for AEs were similar (four vs three, respectively). Common AEs in the AZ-containing arms included pruritus, vomiting, dizziness, and headache.
  
  
  CONCLUSIONS
  Among adults with symptomatic uncomplicated falciparum malaria in Africa, the combination of AZ 1,000 mg and CQ 600-mg base once daily for three days resulted in Day 28 PCR-corrected parasitological clearance rates of ≥98% and was non-inferior to treatment with MQ. AZCQ was well tolerated.
  
  
  BACKGROUND
  ClinicalTrials.gov identifiers NCT00082576 and NCT00367653.
authors.forename: Issaka
authors.initials: I
authors.lastname: Sagara
authors.forename: Abraham R
authors.initials: AR
authors.lastname: Oduro
authors.forename: Modest
authors.initials: M
authors.lastname: Mulenga
authors.forename: Yemou
authors.initials: Y
authors.lastname: Dieng
authors.forename: Bernhards
authors.initials: B
authors.lastname: Ogutu
authors.forename: Alfred B
authors.initials: AB
authors.lastname: Tiono
authors.forename: Peter
authors.initials: P
authors.lastname: Mugyenyi
authors.forename: Ali
authors.initials: A
authors.lastname: Sie
authors.forename: Monique
authors.initials: M
authors.lastname: Wasunna
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Kain
authors.forename: Abdoulaye A
authors.initials: AA
authors.lastname: Djimdé
authors.forename: Shirsendu
authors.initials: S
authors.lastname: Sarkar
authors.forename: Richa
authors.initials: R
authors.lastname: Chandra
authors.affiliation: Global Research and Development, Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA. jeffery.robbins@pfizer.com.
authors.forename: Jeffery
authors.initials: J
authors.lastname: Robbins
authors.forename: Michael W
authors.initials: MW
authors.lastname: Dunne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000962:Antimalarials / Q000008:administration & dosage*; D017963:Azithromycin / Q000008:administration & dosage*; D002738:Chloroquine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D015767:Mefloquine / Q000008:administration & dosage; D008875:Middle Aged; D018512:Parasitemia / Q000175:diagnosis; D010963:Plasmodium falciparum / Q000235:genetics / Q000302:isolation & purification; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome; D014454:Uganda; D055815:Young Adult; D015024:Zambia
chemical_list: D000962:Antimalarials; D017963:Azithromycin; D002738:Chloroquine; D015767:Mefloquine